CCN2 and idiopathic pulmonary fibrosis: Despite inconsistent results in clinical trials for idiopathic pulmonary fibrosis, CTGF remains a central player in fibrosis and could still serve as a potential therapeutic target for orbital fibrosis in GO patients.